Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting  by Dinleyici, Ener Cagri et al.
JO
L
i
E
Z
M
Y
a
U
b
c
d
A
e
f
g
h
i
j
k
R
A
a
h
0 Pediatr (Rio J). 2015;91(4):392--396
www.jped.com.br
RIGINAL ARTICLE
actobacillus  reuteri  DSM  17938  shortens  acute
nfectious diarrhea  in a pediatric  outpatient  setting
ner Cagri Dinleyici a,∗, Nazan Dalgicb, Sirin Guvenc, Ozge Metind, Olcay Yasae,
afer  Kurugol f, Ozden Turelg, Gonul Tanird, Ahmet Sami Yazarc, Veﬁk Aricah,
esut  Sancar i, Adem Karbuzh, Makbule Erenj, Metehan Ozenh, Ates Kara i,
van  Vandenplask
Faculty  of  Medicine,  Department  of  Pediatrics,  Pediatric  Intensive  Care  and  Infectious  Disease  Unit,  Eskisehir  Osmangazi
niversity,  Eskisehir,  Turkey
Division  of  Pediatric  Infectious  Diseases,  Sisli  Etfal  Training  and  Research  Hospital,  Istanbul,  Turkey
Department  of  Pediatrics,  Umraniye  Education  &  Research  Hospital,  Istanbul,  Turkey
Pediatric  Infectious  Disease  Unit,  Dr.  Sami  Ulus  Research  and  Training  Hospital  of  Women’s  and  Children’s  Health  and  Diseases,
nkara, Turkey
Department  of  Pediatrics,  Goztepe  Training  and  Research  Hospital,  SB  Istanbul  Medeniyet  University,  Istanbul,  Turkey
Department  of  Pediatrics,  Faculty  of  Medicine,  Ege  University, I˙zmir,  Turkey
Department  of  Pediatric  Infectious  Disease  Unit,  Faculty  of  Medicine,  Bezmialem  Vakif  University,  Istanbul,  Turkey
Department  of  Pediatrics,  Okmeydani  Education  and  Research  Hospital,  Istanbul,  Turkey
Faculty  of  Pharmacy,  Clinical  Pharmacy  Department,  Marmara  University,  Istanbul,  Turkey
Faculty  of  Medicine,  Pediatric  Infectious  Disease  Unit,  Hacettepe  University,  Ankara,  Turkey
Department  of  Pediatrics,  UZ  Brussel,  Vrije  Universiteit  Brussel,  Brussels,  Belgium
eceived  1  August  2014;  accepted  23  October  2014
vailable  online  16  May  2015
KEYWORDS
Lactobacillus  reuteri
DSM  17938;
Diarrhea;
Abstract
Objective:  Two  randomized  controlled  clinical  trials  have  shown  that  Lactobacillus  (L)  reuteri
DSM 17938  reduces  the  duration  of  diarrhea  in  children  hospitalized  due  to  acute  infectious
diarrhea. This  was  the  ﬁrst  trial  evaluating  the  efﬁcacy  of  L.  reuteri  DSM  17938  in  outpatient
children  with  acute  infectious  diarrhea.Children;Probiotic; Methods:  This  was  a  multicenter,  randomized,  single-blinded,  case  control  clinical  trial  in  chil-
Ambulatory  care dren with  acute  watery  diarrhea.  A  total  of  64  children  who  presented  at  outpatient  clinics
were enrolled.  The  probiotic  group  received  1  ×  108 CFU  L.  reuteri  DSM  17938  for  ﬁve  days  in
addition to  oral  rehydration  solution  (ORS)  and  the  second  group  was  treated  with  ORS  only.
 Please cite this article as: Dinleyici EC, Dalgic N, Guven S, Metin O, Yasa O, Kurugol Z, et al. Lactobacillus reuteri DSM 17938 shortens
cute infectious diarrhea in a pediatric outpatient setting. J Pediatr (Rio J). 2015;91:392--6.
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The  primary  endpoint  was  the  duration  of  diarrhea  (in  hours).  The  secondary  endpoint  was  the
number of  children  with  diarrhea  at  each  day  of  the  ﬁve  days  of  intervention.  Adverse  events
were also  recorded.
Results:  The  mean  duration  of  diarrhea  was  signiﬁcantly  reduced  in  the  L.  reuteri  group
compared  to  the  control  group  (approximately  15  h,  60.4  ±  24.5  h  [95%  CI:  51.0--69.7  h]  vs.
74.3 ±  15.3  h  [95%  CI:  68.7--79.9  h],  p  <  0.05).  The  percentage  of  children  with  diarrhea  was
lower in  the  L.  reuteri  group  (13/29;  44.8%)  after  48  h  than  the  control  group  (27/31;  87%;  RR:
0.51; 95%  CI:  0.34--0.79,  p  <  0.01).  From  the  72nd  hour  of  intervention  onwards,  there  was  no
difference between  the  two  groups  in  the  percentage  of  children  with  diarrhea.  No  adverse
effects related  to  L.  reuteri  were  noted.
Conclusion:  L.  reuteri  DSM  17938  is  effective,  safe,  and  well-tolerated  in  outpatient  children
with acute  infectious  diarrhea.
© 2015  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.
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O  Lactobacillus  reuteri  DSM  17938  reduz  a  diarreia  infecciosa  aguda  no  cuidado
pediátrico  ambulatorial
Resumo
Objetivo:  Dois  ensaios  clínicos  randomizados  controlados  demonstraram  que  o  Lactobacillus
(L) reuteri  DSM  17938  reduz  a  durac¸ão  de  diarreia  em  crianc¸as  hospitalizadas  devido  a  diarreia
infecciosa aguda.  Este  é  o  primeiro  ensaio  que  avalia  a  eﬁcácia  do  L.  reuteri  DSM  17938  em
crianc¸as com  diarreia  infecciosa  aguda  no  ambulatório.
Métodos:  Este  foi  um  ensaio  clínico  multicêntrico,  randomizado,  único  cego,  com  grupos  par-
alelos e  controlado  em  crianc¸as  com  diarreia  aguda.  Um  total  de  64  crianc¸as  internadas  na
clínica ambulatorial  foram  inscritas.  O  grupo  probiótico  recebeu  1  ×  108 CFU  L.  reuteri  DSM
17938 por  cinco  dias,  além  de  uma  soluc¸ão  de  reidratac¸ão  oral  (SRO),  e  o  segundo  grupo  foi
tratado apenas  com  SRO.  O  desfecho  principal  foi  a  durac¸ão  da  diarreia  (em  horas).  O  desfecho
secundário foi  o  número  de  crianc¸as  com  diarreia  em  cada  um  dos  cinco  dias  da  intervenc¸ão.
Os eventos  adversos  também  foram  registrados.
Resultados:  A  durac¸ão  média  da  diarreia  foi  signiﬁcativamente  reduzida  no  grupo  L.  reuteri
em comparac¸ão  ao  grupo  de  controle  (aproximadamente  15  horas;  60,4  ±  24,5  horas  [51,  0--69,
7 horas,  IC  de  95%]  em  comparac¸ão  a  74,3  ±  15,3  horas  [68,  7--79,  9  horas,  IC  de  95%],  p  <  0,05).
O percentual  de  crianc¸as  com  diarreia  foi  menor  no  grupo  L.  reuteri  (13/29;  44,8%)  após  48
horas que  no  grupo  de  controle  (27/31;  87%)  (RR:  0,51;  0,  34--0,  79;  IC  de  95%,  <0,01).  A  partir
da 72a hora  de  intervenc¸ão,  não  havia  nenhuma  diferenc¸a  entre  os  dois  grupos  no  percentual
de crianc¸as  com  diarreia.  Nenhum  efeito  adverso  com  relac¸ão  ao  L.  reuteri  foi  observado.
Conclusão:  O  L.  reuteri  DSM  17938  é  eﬁcaz,  seguro  e  bem  tolerado  por  crianc¸as  com  diarreia
infecciosa  aguda  no  ambulatório.
©  2015  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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Diarrhea  remains  an  important  cause  of  morbidity  and
mortality  in  children  worldwide.1 The  European  Society
of  Paediatric  Gastroenterology,  Hepatology,  and  Nutrition
(ESPGHAN)  and  the  European  Society  of  Paediatric  Infec-
tious  Diseases  (ESPID)  together  published  evidence-based
guidelines  on  the  management  of  acute  gastroenteritis,  and
conﬁrmed  that  rehydration  is  the  key  treatment.  The  guide-
lines  also  stated  that  selected  probiotics  may  reduce  the
duration  and  intensity  of  symptoms  and  can  be  used  as
an  adjuvant  to  oral  rehydration  solution  (ORS).2 Current
evidence  also  indicates  that  probiotic  effects  are  strain-
speciﬁc.3 Various  strains  of  Lactobacillus  reuteri  species
a
e
iave  been  studied  in  acute  diarrhea  and  have  been  found
o  be  beneﬁcial.  L.  reuteri  DSM  17938  is  a  new  probiotic
train  with  removed  transferable  resistance  traits  for  tetra-
ycline  and  lincomycin  from  the  original  L.  reuteri  ATCC
5730  strain.4 It  has  been  previously  reported  that  L.  reuteri
SM  17938  reduced  the  duration  of  diarrhea  and  the  length
f  hospital  stay  in  children  requiring  hospitalization  due
o  acute  infectious  diarrhea.5 A  recent  meta-analysis  of  L.
euteri  DSM  17938  in  children  with  acute  infectious  diar-
hea  showed  reduced  duration  of  diarrhea  and  concluded
hat  outpatient  data  and  country-speciﬁc  cost-effectiveness
nalyses  are  needed.6 This  study  is  the  ﬁrst  report  of  the
ffects  of  L.  reuteri DSM  17938  on  acute  infectious  diarrhea
n  an  outpatient  pediatric  setting.
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Acute gastroenteritis
Assessed for eligibility (n = 64)
Discontinued intervention (antibiotic
prescription; n = 3) 
Final: n = 29 
Lactobacillus reuteri DSM 17038 + oral
rehydration solution (ORS)
Allocated to intervention (n = 32)  
♦ Received allocated intervention (n = 32)
Allocation
Follow-up/analysis
Enrollment
Discontinued intervention (antibiotic
prescription; n = 1) 
Final: n = 31 
Control group (ORS) 
Allocated to intervention (n = 32) 
♦ Received allocated intervention (n = 32)
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sFigure  1  Flow  dia
atient and methods
his  was  a  multicenter,  randomized,  single-blinded,  case
ontrol  clinical  trial  in  children  of  both  genders,  aged
etween  3  and  60  months,  with  acute  infectious  diarrhea
deﬁned  as  the  passage  of  three  or  more  loose  or  watery
tools  per  day)  lasting  12--72  h  before  presentation  at  the
utpatient  clinic.  The  main  investigator  (ECD)  did  not  enroll
hildren  and  was  blinded  to  the  treatment  of  the  patients.
pproval  for  the  study  was  granted  by  the  Local  Ethics
ommittee  and  an  informed  consent  was  obtained  from
he  parents  of  the  children.  This  study  was  registered  at
ww.clinicaltrials.gov (NCT01927094).
Children  who  presented  at  the  outpatient  clinic  with
cute  infectious  diarrhea,  and  who  were  followed  up  with
mbulatory  care  were  enrolled  in  the  study.  Exclusion  crite-
ia  were  need  for  hospitalization,  use  of  antibiotics  or
robiotics  for  one  month  prior  to  a  new  episode  of  diarrhea,
evere  malnutrition,  or  severe  chronic  underlying  disease,
ncluding  immunocompromising  conditions.
All  children  were  randomly  assigned  to  the  probiotic  or
ontrol  group  using  a  computer-generated  randomization
ist.  Block  randomization  was  applied  with  a  computer-
enerated  random  number  list  by  the  main  investigator
ECD),  who  did  not  enroll  any  patients.  The  ﬁrst  group
eceived  the  ﬁve  drops  containing  1  ×  108 CFU  L.  reuteri  DSM
7938  (BioGaia®,  Stockholm,  Sweden)  for  ﬁve  days,  in  addi-
ion  to  ORS.  The  second  group  received  ORS  only  (control
roup).  The  probiotics  preparations  were  provided  by  the
istribution  company  (Eczacibasi)  in  Turkey.  Hypo-osmolar
RS  (glucose  20  g;  sodium  60  mmol/L;  potassium  20  mmol/L;
icarbonate  30  mmol/L)  was  used.  The  primary  endpoint
as  the  duration  of  diarrhea  (in  hours).  The  secondary  end-
oint  was  the  number  of  children  with  diarrhea  at  each  day
f  the  ﬁve  days  of  the  intervention.  Adverse  events  were  also
i
(
7 of  the  study  group.
ecorded.  The  duration  of  diarrhea  was  deﬁned  as  the  time
n  hours  from  admission  until  cessation  of  diarrhea,  which  in
urn  was  deﬁned  as  the  ﬁrst  normal  stool  according  to  the
ristol  score  (a  score  of  <5  was  considered  as  normalization
f  the  stools).
The  sample  size  needed  was  calculated  based  on  the
ean  duration  of  diarrhea  and  standard  deviation  (SD)  from
revious  similar  studies.  With  the  assumption  of  mean  differ-
nce  on  duration  of  diarrhea  of  one  day  (24  h)  between  the
reatment  and  control  group,  the  authors  calculated  that
 sample  of  64  children  would  be  required  for  the  study  to
ave  80%  power  with  a signiﬁcance  level  =  0.05  and  sigma  =  2
two  tailed  test).  Statistical  analysis  was  performed  using
PSS  software,  version  16.0  (SPSS  Inc.,  IL,  USA).  Variables
ere  tested  for  normal  distribution  and  compared  using  the
ann--Whitney  U-test  and  t-test  (for  mean  difference)  and
2 or  Fisher’s  exact  tests,  as  appropriate.  MedCalc® pro-
ram  (Microsoft  Partner  Network,  USA)  was  performed  to
alculate  relative  risk  (RR).  Statistical  signiﬁcance  was  set
t  p  <  0.05.
esults
he  study  included  64  children.  After  exclusion  of  three  chil-
ren  from  the  L.  reuteri group  and  one  child  from  the  control
roup  due  to  antibiotic  prescription  post-randomization
Fig.  1),  a  total  of  60  remained  for  evaluation;  29  (20  male,  9
emale)  in  the  L.  reuteri group  and  31  (22  male,  nine  female)
n  the  control  group.  The  demographic  ﬁndings,  mean  dura-
ion  of  diarrhea  before  intervention  and  mean  number  of
tools  at  24  h  prior  to  inclusion  are  summarized  in  Table  1.The  mean  duration  of  diarrhea  was  signiﬁcantly  reduced
n  the  L.  reuteri  group  when  compared  to  the  control  group
approximately  15  h;  60.4  ±  24.5  h  [95%  CI:  51.0--69.7  h]  vs.
4.3  ±  15.3  h [95%  CI:  68.7--79.9  h];  p  <  0.05;  Table  2).
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Table  1  Demographic  and  clinical  ﬁndings  of  the  study  groups.
Lactobacillus  reuteri  DSM  17938  (n  =  29)  Control  group  (n  =  31)
Age  (months)  27.9  ±  18.2  22.6  ±  14.4
Gender 20  boys,  9  girls  22  boys,  9  girls
Mean number  of  stools  during  the  24  h  prior  to  inclusion  7.13  ±  3.8  6.1  ±  0.9
Mean duration  of  diarrhea  before  intervention  (hours)  18.1  ±  6.5  20.1  ±  8.7
Values expressed as mean ± SD.
Table  2  Duration  of  diarrhea  in  study  groups.
Lactobacillus
reuteri  DSM  17938
(n =  29)
Control  group
(n =  31)
Duration  of
diarrhea  (hours)
60.4  ±  24.5a 74.3  ±  15.3
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pValues are expressed as mean ± SD (95% CI).
a p = 0.01; L. reuteri vs. control group.
At  the  48th  hour  of  the  study,  45%  of  the  children  receiv-
ing  L.  reuteri DSM  17938  had  watery  diarrhea,  while  this
was  still  the  case  in  87%  of  the  children  in  the  control  group
(13/29;  44.8%  vs.  27/31;  87%;  RR:  0.51;  95%  CI:  0.34--0.79;
p  <  0.01).  From  the  72nd  hour  of  the  intervention,  the  per-
centage  of  children  without  diarrhea  was  similar  between
the  groups  (Table  3).  No  adverse  effects  related  to  L.  reuteri
DSM  17938  were  observed.
Discussion
The  results  of  the  present  study  showed  that  ORS  in  combi-
nation  with  ﬁve  days  of  L.  reuteri  DSM  17938  reduced  the
duration  of  acute  infectious  diarrhea  to  approximately  15  h
in  children  aged  between  3  and  60  months.  The  effect  was
mainly  observed  after  48  h  of  intervention,  when  55%  of  the
children  in  the  intervention  group  were  diarrhea-free,  while
this  was  the  case  in  only  13%  in  the  control  group.  In  a  previ-
ous  study,  performed  by  the  same  study  team  and  with  the
same  design,  except  for  the  fact  that  the  study  was  applied
to  hospitalized  children,  127  children  aged  3--60  months
were  enrolled.  In  hospitalized  children,  the  administration
of  L.  reuteri  DSM  17938  reduced  the  duration  of  diarrhea  sig-
niﬁcantly  to  approximately  33  h.5 The  effect  (percentage  of
children  without  diarrhea)  of  L.  reuteri  DSM  17938  started  to
be  observed  after  24  h  of  intervention  and  was  greatest  after
48  and  72  h.  It  was  observed  also  that  the  mean  length  of  hos-
pital  stay  was  shortened  by  more  than  24  h  in  the  L.  reuteri
e
ﬁ
e
Table  3  Percentage  of  children  with  diarrhea  in  study  groups.
Lactobacillus  reuteri  DSM  17938  (n  =  29)  Co
24th  hour  25/29  (86.2%)  31/
48th hour  13/29  (44.8%)  27/
72nd hour  5/29  (17.2%)  4/
96th hour  1/29  (3.4%)  1/
120th hour  0/29  (0%)  0/SM  17938  group.5 Francavilla  et  al.7 performed  a  random-
zed  double-blinded,  placebo-controlled  clinical  trial  on  74
hildren  aged  6--36  months  with  acute  diarrhea,  random-
zed  to  receive  L.  reuteri  DSM  17938  or  placebo  for  seven
ays,  in  three  hospitals  in  Southern  Italy.  Compared  with  the
lacebo  group,  the  L.  reuteri  DSM  17938  group  presented  a
igniﬁcant  reduction  in  the  duration  of  diarrhea,  in  the  risk
f  watery  diarrhea  on  day  2  and  day  3,  and  in  the  risk  of
elapse  of  diarrhea,  although  no  reduction  of  the  duration
f  hospitalization  was  observed.7 Szajewska  et  al.6 pooled
he  data  from  these  two  RCTs  of  hospitalized  children,  con-
rming  that  L.  reuteri  DSM  17938  signiﬁcantly  reduced  the
uration  of  diarrhea  to  approximately  32  h  and  increased
he  chance  of  cure  on  day  3.6 Two  independent  studies,  one
n  Indonesia  and  one  in  Mexico,  demonstrated  that  the  pro-
hylactic  use  of  L.  reuteri  DSM  17938  reduces  the  frequency
nd  duration  of  diarrheal  episodes,8,9 although  their  clinical
elevance  can  be  questioned.10 L.  reuteri  DSM  17938  was
ell  tolerated,  and  no  associated  adverse  events  have  been
eported  in  any  trial.6
The  current  study  had  some  limitations,  as  it  was  not  a
ouble-blinded,  placebo-controlled  clinical  trial.  To  access
tool  consistency,  the  Bristol  Stool  Form  Scale  was  used,
hich  has  a  limited  validation  for  the  youngest  children,
lthough  it  offers  a  more  objective  form  of  assessing  stool
onsistency  rather  than  just  relying  on  the  perceptions  of
aregivers.11 The  duration  of  diarrhea  was  used  as  the  pri-
ary  endpoint,  which  is  not  considered  optimal.  However,
here  is  a  major  reluctance  of  caregivers  and  healthcare
roviders  to  conduct  the  cumbersome  stool  collection.
he  question  of  generalization  of  ﬁndings  in  clinical  tri-
ls,  speciﬁcally  on  infectious  gastroenteritis  and  probiotics,
s  challenging.  However,  these  ﬁndings  can  be  considered
s  generalized,  since  worldwide  viral  gastroenteritis  is  the
ost  common  cause.  Moreover,  as  a  multi-center  study,  the
articipants  came  from  urban  and  rural  regions,  including
conomically  developed  and  poor  areas.  Therefore,  these
ndings  are  likely  to  allow  for  generalization.
The  Working  Group  on  Probiotics  of  the  European  Soci-
ty  for  Pediatric  Gastroenterology,  Hepatology  and  Nutrition
ntrol  group  (n  =  31)  Relative  risk  (95%  CI)  p
31  (100%)  0.86  (0.74--1.01)  p  >  0.05
31  (87.0%)  0.51  (0.34--0.79)  p  <  0.01
31  (12.9%)  1.34  (0.4--4.5)  p  >  0.05
31  (3.2%)  1.07  (0.07--16.3)  p  >  0.05
31  (0%)  NA  p  >  0.05
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ESPGHAN)  concluded  that  the  use  of  L.  reuteri  DSM  17938
hould  be  considered  in  the  management  of  acute  gastroen-
eritis  as  an  adjunct  intervention  to  ORS.3 Probiotics  may  be
f  help  for  the  management  of  acute  diarrhea.  However,  the
ffect  is  strain-speciﬁc,  and  efﬁcacy  needs  to  be  proven  in
ifferent  settings,  such  as  hospital  or  outpatients  settings.
he  results  of  the  present  study  have  shown  that  L.  reuteri
SM  17938  as  an  adjunct  to  ORS  therapy  is  efﬁcacious  in  the
reatment  of  acute  diarrhea,  reducing  the  duration  of  the
isease  in  an  outpatient  setting.
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